Drug Profile
DCB BO 1301
Alternative Names: DCB BO1301Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Development Center for Biotechnology
- Developer Chung Mei Biopharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Malignant-melanoma in Taiwan (PO, Capsule)
- 13 Dec 2016 Preclinical trials in Malignant melanoma in Taiwan (PO) before December 2016